Nuvig Therapeutics Announces First Patient Dosed in Phase 2 CIDP Trial of NVG-2089 and Presentation of Phase 1 Data

NVG-2089 is a recombinant Fc fusion protein designed to replicate key immunomodulatory functions of IVIg with greater consistency, scalability, and patient convenience Phase 1 data show NVG-2089 was well tolerated with no serious or severe adverse events, supporting advancement into Phase 2 development for CIDP Menlo Park, Calif., May 14, 2025 – Nuvig Therapeutics, Inc.,… The post Nuvig Therapeutics Announces First Patient Dosed in Phase 2 CIDP Trial of NVG-2089 and Presentation of Phase 1 Data appeared first on Nuvig Therapeutics .